FIELD OF THE INVENTION
This invention relates 3,6-disubstituted azabicyclo hexanes derivatives .
The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors.
The invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.
BACKGROUND OF THE INVENTION
Muscarinic receptors as members of the G Protein Coupled Receptors (GPCRs) are composed of a family of 5 receptor sub-types (M1, M2, M3, M4 and M5) and are activated by the neurotransmitter acetylcholine. These receptors are widely distributed on multiple organs and tissues and are critical to the maintenance of central and peripheral cholinergic neurotransmission. The regional distribution of these receptor sub-types in the brain and other organs has been documented. For example, the M1 subtype is located primarily in neuronal tissues such as cereberal cortex and autonomic ganglia, the M2 subtype is present mainly in the heart where it mediates cholinergically induced bradycardia, and the M3 subtype is located predominantly on smooth muscle and salivary glands (Nature, 1986; 323: 411; Science, 1987; 237: 527). A review in Current Opinions in Chemical Biology, 1999; 3: 426, as well as in Trends in Pharmacological Sciences, 2001; 22: 409 by Eglen et. al., describe the biological potentials of modulating muscarinic receptor subtypes by ligands in different disease conditions like Alzheimer's disease, pain, urinary disease condition, chronic obstructive pulmonary disease etc.
A review in J. Med. Chem., 2000; 43: 4333 by Christian C. Felder et. al. describes therapeutic opportunities for muscarinic receptors in the central nervous system and elaborates on muscarinic receptor structure and function, pharmacology and their therapeutic uses.
The pharmacological and medical aspects of the muscarinic class of acetylcholine agonists and antagonists are presented in a review in Molecules, 2001, 6: 142.
N.J.M. Birdsall et. al. in Trends in Pharmacological Sciences, 2001; 22: 215 have also summarized the recent developments on the role of different muscarinic receptor subtypes using different muscaranic receptors of knock out mice.

Muscarinic agonists such as muscarine and pilocarpine and antagonists such as atropine have been known for over a century, but little progress has been made in the discovery of receptor subtype-selective compounds making it difficult to assign specific functions to the individual receptors. Although classical muscarinic antagonists such as atropine are potent bronchodilators, their clinical utility is limited due to high incidence of both peripheral and central adverse effects such as tachycardia, blurred vision, dryness of mouth, constipation, dementia, etc. Subsequent development of the quarterly derivatives of atropine such as ipratropium bromide are better tolerated than parenterally administered options but most of them are not ideal anti-cholinergic bronchodilators due to lack of selectivity for muscarinic receptor sub-types. The existing compounds offer limited therapeutic benefit due to their lack of selectivity resulting in dose limiting side-effects such as thirst, nausea, mydriasis and those associated with the heart such as tachycardia mediated by the M2 receptor.
Annual review of Pharmacological Toxicol., 2001; 41: 691, describes the pharmacology of the lower urinary tract infections. Although anti muscarinic agents such as oxybutynin and tolterodine that act non-selectively on muscarinic receptors have been used for many years to treat bladder hyperactivity, the clinical effectiveness of these agents has been limited due to the side effects such as dry mouth, blurred vision and constipation. Tolterodine is considered to be generally better tolerated than oxybutynin. (W.D.Steers et. al. in Curr. Opin. Invest. Drugs, 2: 268, C.R. Chappie et. al. in Urology. 55: 33), Steers WD, Barrot DM, Wein AJ, 1996, Voiding dysfunction: diagnosis classification and management. In "Adult and Pediatric Urology," ed. JY Gillenwatter, JT Grayhack, SS Howards, JW Duckett, pp 1220-1325, St. Louis, MO; Mosby. 3rd edition.) ;
Despite these advances, there remains a need for development of new highly selective muscarinic antagonists which can interact with distinct subtypes, thus avoiding the occurrence of adverse effects.
Compounds having antagonistic activity against muscarinic receptors have been described in Japanese patent application Laid'Open Number 92921/1994 and 135958/1994; WO 93/16048; U.S. Patent No. 3,176,019; GB 940,540; EP 0325 571; WO 98/29402; EP 0801067; EP 0388054; WO 9109013; U.S. Patent No. 5,281,601. U.S. Patent Nos. 6,174,900, 6,130,232 and 5,948,792; WO 97/45414 are related to 1,4-disubstituted piperidine derivatives; WO 98/05641 describes fluorinated, 1,4-disubstitued piperidine derivatives; WO 93/16018 and W096/33973 are other close art references.

A report in J. Med. Chem., 2002; 44:984, describes cyclohexylmethyl piperidinyl triphenylpropioamide derivatives as selective M3 antagonist discriminating against the other receptor subtypes.
SUMMARY OF THE INVENTION
The present invention provides 3,6-disubstituted azabicyclo hexanes derivatives as muscarinic receptor antagonists and are useful as therapeutic or prophylactic agents for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems and process for the syntheses of the compounds.
The invention also provides pharmaceutical compositions containing the compounds, and which may also contain acceptable carriers, excipients or diluents which are useful for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems.
The invention further includes pharmaceutical compositions comprising the compounds of the present invention, their enantiomers, diastereomers, prodrugs, N-oxides, polymorphs, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters or metabolites, in combination with a pharmaceutically acceptable carrier and optionally included excipients.
Other advantages of the invention will be set forth in the description which follows, and in part will be apparent from the description or may be learnt by the practice of the invention.
In accordance with one aspect of the present invention, there are provided 3,6-disubstituted azabicyclo hexanes derivatives having the structure of Formula I:
(Formula Removed)
Formula I
wherein Ar represents an aryl;
R1 represents hydroxy;
R2 represents C3-C7 cycloalkyl ring in which any 1-4 hydrogen atoms are substituted with halogen (e.g. F, CI, Br, I), carbamoyl or lower alkyl; W represents (CH2)P, where p represents 0 to 1; X represents no atom;

Y represents no atom;
R3 represents hydrogen or lower alkyl;
R6 and R7 are independently selected from H, lower alkyl,; and R4 represents C1-C15 saturated or unsaturated aliphatic hydrocarbon (straight chain or branched) in which any 1 to 6 hydrogen atoms may be substituted with the group independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl having 1 to 2 hetero atoms selected from the group consisting of nitrogen, oxygen and sulphur atom.
In accordance with another aspect of the present invention, there is provided the use of the compounds in the preparation of medicaments for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic receptors, comprising administering to a patient in need thereof, an effective amount of muscarinic receptor antagonist compounds as described above.
In accordance with yet another aspect of the present invention, there is provided the use of the compounds in the preparation of medicaments for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory system such as bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, etc.; urinary system which induce such urinary disorders as urinary incontinence, as lower urinary tract symptoms (LUTS), etc.; and gastrointestinal system such as irritable bowel syndrome, obesity, diabetes and gastrointestinal hyperkinesis, wherein the disease or disorder is associated with muscarinic receptors.
In accordance with another aspect of the present invention, there are provided processes for preparing the compounds as described above,
The compounds of the present invention exhibit significant potency in terms of their activity, which was determined by in vitro receptor binding and functional assays. Some of the compounds of the present invention were found to be potent muscarinic receptor antagonists with high affinity towards M3 receptors. Therefore, the present invention provides pharmaceutical compositions for treatment of diseases or disorders associated with muscarinic receptors. Compounds and compositions described herein can be administered orally or parenterally.

DETAILED DESCRIPTION OF THE INVENTION
The compounds described herein may be prepared by techniques well known in the art and familiar to the average synthetic organic chemist. In addition, the compounds described herein may be prepared by the following reaction sequence as shown in Scheme I.
(Scheme Removed)
The preparation comprises condensing a compound of Formula VI with the compound of Formula V wherein Ar; R1; R2; W; X; Y; R3; R6 and R7 are the same as defined earlier; and P is any group which can be used to protect an amino group, for example, benzyl, t-butyloxy carbonyl, in the presence of a condensing agent to give a

protected compound of Formula VII, which on deprotection through reaction with a deprotecting agent in an organic solvent gives an unprotected compound of Formula VIII which is finally N-alkylated or benzylated with a suitable alkylating or benzylating agent L-R4 to give a compound of Formula I wherein L is any leaving group and R4 is the same as defined earlier.
The reaction of the compound of Formula VI with a compound of Formula V to give a compound of formula VII can be carried out in the presence of a condensing agent, for example, l-(3-dimethylamino propyl)3-ethyl carbodiimide hydrochloride (EDC) or 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
The reaction of the compound of Formula VI with a compound of Formula V to give a compound of Formula VII can be carried out in a suitable solvent, for example, N,N-dimethylformamide, dimethylsulfoxide, toluene or xylene at a temperature ranging from about 0°C to about 140°C.
The deprotection of the compound of Formula VII to give a compound of Formula VIII can be carried out with a deprotecting agent, for example, palladium on carbon, trifluoroacetic acid (TFA) or hydrochloric acid.
The deprotection of the compound of Formula VII to give a compound of Formula VIII can be carried out in a suitable organic solvent, for example, methanol, ethanol, tetrahydrofuran or acetonitrile at a suitable temperature ranging from about 10°C to about
50°C. !
The N-alkylation or benzylatioh of the compound of Formula VIII to give a compound of Formula I can be carried out with a suitable alkylating or benzylating agent, L-R4 wherein L is any leaving group, known in the art, for example, halogen, O-mestyl or O-tosyl group.
The N-alkylation or benzylation of the compound of Formula VIII to give a compound of Formula I can be carried out in a suitable organic solvent such as N,N-dimethylformamide, dimethylsulfoxide, tetrahydrofuran or acetonitrile, at temperature ranging from about 25°C to about 100°C.

(Scheme Removed)
The compound of Formula IV of the present invention may be prepared by the reaction sequence as shown in Scheme II. The preparation comprises condensing a compound of Formula IX (prepared following the procedure described in J. Med Chem., 2000; 43: 5017-5029) wherein R9 is H or F and R10 is F, with the compound of Formula X wherein R3 represents hydrogen, lower alkyl, or CO2C(CH3)3, and P is any group, for example, benzyl, t-butyloxy carbonyl which can be used to protect an amino group, in the presence of a condensing agent to give a protected compound of Formula XI, which on deprotection through reaction with a deprotecting agent in an organic solvent gives an unprotected

compound of Formula XII which is finally N-alkylated or benzylated with a suitable alkylating or benzylating agent, L-R4 to give a compound of Formula IV wherein L is any leaving group and R4 is the same as defined earlier.
The reaction of the compound of Formula IX with the compound of Formula X to give a compound of Formula XI can be carried out in the presence of a condensing agent, for example, l-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (EDC) or 1, 8-diazabicyclo [5.4.0] undec-7-ene (DBU).
The reaction of the compound of Formula IX with the compound of Formula X to give a compound of Formula XI can be carried out in a suitable solvent, for example, N,N-dimethylformamide, dimethylsulphoxide, toluene or xylene at a temperature ranging from about 0°C to about 25°C.
The deprotection of the compound of Formula XI to give a compound of Formula XII can be carried out in a suitable organic solvent, for example, methanol, ethanol, tetrahydrofuran or acetonitrile at a temperature ranging from about 10°C to about 50°C.
The N-alkylation or benzylation of the compound of Formula XII to give a compound of Formula IV can be carried out with a suitable alkylating or benzylating agent, L-R4 wherein L is any leaving group, known in the art, for example, halogen, O-mestyl or O-tosyl group.
The N-alkylation or benzylation of the compound of Forrnula XII to give a compound of Formula IV can be carried out in a suitable organic solvent such as N, N-dimethylformamide, dimethylsulphoxide, tetrahydrofuran or acetonitrile, at temperature ranging from about 0°C to about 100°C.
The conversion of the hydroxyl or oxo group (s) to fluorine atoms(s) normally can be effected by causing the compound to react in an inert solvent which is not detrimental to the reaction, e.g., methylene chloride, chloroform, tetrahydrofuran, acetonitrile, DMSO or in pyridine or in the absence of a solvent, using one equivalent to an excessive amount of fluorinating agent belonging to a class of diethylamino sulphurtrifluoride, at temperatures ranging from about -80°C to about 100°C.
In the above schemes, where specific bases; condensing agents, protecting groups, protecting agents, N-alkylating or benzylating agents, solvents, etc., are mentioned, it is to be understood that other basic condensing agents, protecting group, deprotecting agents, N-alkylating/benzylating agents, solvents, etc., known to those skilled in the art may be

used. Similarly, the reaction temperature and duration may be adjusted according to the desired needs.
An illustrative list of particular compounds which are capable of being produced
by Schemes I & II include:
COMPOUND NO. CHEMICAL NAME
1. (2S)-(1α, 5α, 6α)-6-N-[3-benzyl-3- azabicyclo[3.1.0]-hexyl]-2-[(lR or lS)-3-oxocyclohexyl]-2-hydroxy-2-phenylacetamide.
2. (2S)-(1α, 5α, 6α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyl]-2[(1R or 1S, 3R or 3S)-3-fluorocyclohexyl ]-2-hydroxy-2-phenylacetamide.
3. (2S)-(1α, 5α, 6α)-6-N-[3-benzyl-3-azabicydlo[3.1.0]-hexyl]-2-[(1R or 1S, 3R or 3S)-3-fluorocyclopentyl]-2-hydroxy-2-phenylacetamide.
4. (2S)-(1α, 5α, 6α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyl]-2-[(lR or lS)-3, 3-difluorocyclohexyl]-2-hydroxy-2-phenylacetamide.
5. (2S)-(1α, 5α, 6α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyl]-2-[(lR or lS)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide.
6. (2R)-(1α, 5α, 6α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide.
7. (2S)- (1α, 5α, 6α)-6-N- [3-(2-(3,4-methylenedioxyphenyl) ethyl)-3-azabicyclo [3.1.0]-hexyl]-2-[(lR or lS)-3, 3-difluorocyclohexyl]-2-hydroxy-2-phenylacetamide.
8. (2S)-(1α, 5α, 6α)-6-N-[3-(2-(3, 4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(lR or lS)-3, 3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide.
9. (2R)-(1α, 5α, 6α)-6-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(lR or lS)-3, 3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide.
10. (2S)-(1α, 5α, 6α)-6-N-[3-(2-(3, 4-methyle;ne4ioxyphenyl)ethyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S, 3R or 3S)-3-fluorocyclohexyl]-2-hydroxy-2-phenylacetamide.
11. (2S)-(1α, 5α, 6α)-6-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S, 3R or 3S)-3-fluorocyclopentyl]-2-hydroxy-2-phenylacetamide.
12. (2S)-(1α, 5α, 6α)-6-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S)-3, 3-difluorocyclohexyl]-2-hydroxy-2-phenylacetamide.
13. (2S)-(1α, 5α, 6α)-6-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S)-3, 3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide.
14. (2R)-(1α, 5α, 6α)-6-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S)-3, 3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide.
15. (2S)-(1α, 5α, 6α)-6-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or
1S, 3R or 3S)-3-fluorocyclohexyl]-2-hydroxy-2-phenylacetamide.
16. (2S)-(1α, 5α, 6α)-6-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or
1S, 3R or 3S)-3-fluorocyclopentyl]-2-hydroxy-2-phenylacetamide.
Compounds or compositions disclosed may be administered to an animal
for treatment orally, or by parenteral route. Pharmaceuticals compositions disclosed

herein can be produced and administered in dosage units, each unit containing a certain amount of at least one compound described herein and/or at least on physiologically acceptable salt addition thereof. The dosage may be varied over extremely wide limits as the compounds are effective at low dosage levels and relatively free of toxicity. The compounds may be administered in the low micromolar concentration, which is therapeutically effective, and the dosage may be increased as desired up to the maximum dosage tolerated by the patient.
The present invention also includes within its scope prodrugs of the compounds of Formulae I, II, III, and IV. In general, such prodrugs will be functional derivatives of these compounds, which readily are converted in vivo into the defined compounds. Conventional procedures for the selection and preparation of suitable prodrugs are known.
The present invention also includes the enantiomers, diastereomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts of these compounds as well as metabolites having the same type of activity. The present invention further includes pharmaceutical composition comprising the molecules of Formulae I, II, III, and IV or prodrugs, metabolite enantiomers, diastereomers. N-oxides, polymorphs, solvates or pharmaceutically acceptable salts thereof, in combination with pharmaceutically acceptable carrier and optionally included excipients.
The examples mentioned below demonstrate the general synthetic procedure as well as the specific preparation of the particular compound. The examples are provided to illustrate particular aspects of the disclosure and should not be constrained to limit the scope of the present invention, as defined by the claims.
Experimental Details Various solvents, such as acetone, methanol, pyridine, ether, tetrahydrofuran, hexanes, and dichloromethane, were dried using various drying reagents according to the procedure described in the literature. IR spectra were recorded as nujol mulls or a thin neat film on a Perkin Elmer Paragon instrument, Nuclear Magnetic Resonance (NMR) were recorded on a Varian XL-300 MHz instrument using tetramethylsilane as an internal standard.
Example 1
Preparation of (2S)-(1α, 5 α, 6 α)-6-N-[3-benzyl-3-azabicyclo[3.1.01-hexyl]-2-[lR or 1S)-3-oxocyclohexyl] -2-hydroxy-2-phenylacetamide (Compound No. 1).
Step-a: Synthesis of (2S, 5S)-2-tert-butyl-5-phenyl-l, 3-dioxolan-4-one.

The compound was synthesized following the procedure described in J. Org. Chem., 2000; 65: 6283-6287, using S-(+)-Mandelic acid.
Step-b: Synthesis of (2S, 5S)-2-tert-butyl-5-[(lR or 1S)-3-oxocyclohexyl]-5-phenyl-13-dioxolan-4-one.
Lithium diisopropylamide (6.9 mmol) was added to a solution of compound of
step a (4.6 mmol) in tetrahydrofuran (40 ml) containing 2 ml of hexamethyl
phosphoramide and precooled to -78°C under nitrogen atmosphere. The reaction mixture
was stirred for 1 hour at the same temperature, and then cyclohexenone (9.2 mmol) diluted
with 3 ml of THF was added to the reaction mixture. The mixture was further stirred for 3
hours at the same temperature. The reaction mixture was diluted with ethyl acetate,
washed with saturated ammonium chloride and then with water. The organic layer was
dried and the residue obtained after removing the solvent was purified by column
chromatography (100-200 mesh, silica gel), eluting the compound with 10% ethyl acetate-
hexane mixture.
1HNMR (CDCl3): 7.67-7.31 (m, 5ArH), 5.42 (d, 1H), 2.48-2.0 (m, 8H), 0.95-0.90 (d, 9H).
IR (DCM): 1714 and 1790 cm-1
Step-c: Synthesis of (2S)-[(1R or 1S)-3-oxocyclohexyl]-2-hydroxy-2-phenylacetic acid.
The compound of step b (1 mmol) was dissolved in 5 ml methanol and aqueous sodium hydroxide (3N, 5 ml) was added. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, diluted with water and acidified with concentrated hydrochloric acid. It was extracted with ethyl acetate. The residue obtained after removing the solvents was purified by column chromatography (100-200 mesh, silicagel), eluting the compound with 20% ethyl acetate-hexane mixture.
Step-d: Synthesis of (1α, 5α, 6α)-6-amino-3-benzyl-3-azabicyclo[3.1.0]hexane.
This was synthesized by following the procedure of T.F. Braish, et. al., Synlett. 1100, (1996).
Step-e; Synthesis of (2S)-(1α, 5α. 6α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S)-3-oxocyclohexyl]-2-hydroxy-2-phenylacetamide ,
A solution of compound obtained at step c (121 mmol) and (1α, 5α, 6α)-6-
amino-3-benzyl-3-azabicyclo[3.1.0]-hexane (1.45 mmol) was dissolved in
dimethylformamide (5 ml) and cooled to 0°C. N-methylmorpholine (2.42 mmol) and 1-
hydroxybenzotriazole (1.33 mmol) were added to the reaction mixture and stirred for 30

minutes at the same temperature. l-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (1.21 mmol) was added to the reaction mixture and the reaction mixture stirred at 0°C for 1 hour and then at room temperature for 2 days. The reaction mixture was taken in ethyl acetate, washed with water, and dried. The residue obtained after removing the solvent was purified by column chromatography (100-200 mesh, silica gel), eluting the compound with ethyl acetate-hexane mixture.
IR (DCM): 1655 and 1706 cm-1
Example 2
Preparation of (2S)-(1α, 5α, 6α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or
1S, 3R or 3S)-3-fluorocyclohexyl]-2-hydroxy-2-phenylacetamide (Compound No. 2)
Step-a: Synthesis of (2S)-tert-butyl-5-[(1R or 1S, 3R or 3S)-3-hydroxycyclohexyl]-5-phenyl-1, 3-dioxolan-4-one.
The compound of Example 1, Step-b (1 mmol) was dissolved in methanol (5 ml)
and cooled to 0°C. Sodium borohydride (2 mmol) was added in small lots and the
reaction mixture was stirred at 0°C for 1 hour. The solvent was removed under reduced
pressure, the residue taken in ethyl acetate and washed with water. The organic layer was
dried and the residue obtained after removal of solvents was used as such.
1HNMR (CDC13): 7.66-7.28 (m, 5ArH), 5.40 (d, 1H), 3.6-3.4 (m, 1H), 2.04 (s, 4H), 1.21 (m, 5H), 0.92 (s, 9H), IR (DCM): 1790 cm-1
Step-b: Synthesis of (2S, 5S)-2-tert-butyl-5-[(1R or 1S. 3R or 3S)-3-fluorocyclohexyl]-5-phenyl-1, 3-dioxolan-4-one.
To the compound of step-a (1 mmol) in dichloromethane (10 ml) at 0°C, was
added diethylamino sulfur trifluoride (DAST),.(1.2 mmol) and the reaction mixture was
stirred at room temperature overnight. The reaction mixture was cooled to 0°C and
quenched with water. The organic layer was separated and the aqueous layer was
extracted with dichloromethane. The organic layer was dried and the residue obtained
after removing the solvent was purified by column chromatography (100-200 mesh, silica
gel), eluting the compound with ethyl acetate-hexane mixture.
m.pt: 136-139°C, 1HNMR (CDCl3): 7.68-7.26 (m, 5ArH), 5.37 (t, 1H), 4.89 (m, 1H), 2.4 (m, 1H), 2.0-1.24 (m, 6H), 0.89 (d, 9H), IR (KBr): 1787cm-1
Step-c: Synthesis of (2S)-[(1R or 1S, 3R or 3S)-3-fluorocyclohexyl]-2-hydroxy-2-phenyl acetic acid.
The compound was synthesized following the procedure of Example 1, step-c,
using (2S)-2-tert-butyl-5- [(1R or 1S, 3R or 3S)-3-fluorocyclohexyl]-5-phenyl-l, 3-

dioxolan-4-one instead of (2S)-2-tert-butyl-5- [1R or lS)]-3-oxocyclohexyl]-5-phenyl-l, 3-dioxolan-4-one.
Step-d: Synthesis of (2S)-(1α, 5α, 6α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-2-[(1R or 1S. 3R or 3S)-3-fluorocyclohexyl]-2-hydroxy-2-phenylacetamide
The title compound was synthesized following the procedure of Example-1, step-e,
using (2S)-[(1R or 1S, 3R or 3S)-3-fluorocyclohexyl]-2-hydroxy-2-phenylacetic acid
instead of (2S)-[(1R or lS)-3-oxocyclohexyl]-2-hydroxy-2-phenylacetic acid.
1HNMR (CDCl3): 7.54-7.19 (m, lOArH), 4.5 (m, 1H), 3.55 (s, 2H), 3.01 (m, 2H), 2.7 (m, lH),IR(KBr): 1656 cm-1
Example 3
Preparation of (2S)-(1α, 5α, 6α)-6-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl]-2-[(1R or
1S, 3R or 3S)-3-fluorocyclopentyl]-2-hydroxy-2-phenylacetamide (Compound No. 3)
Step-a: Synthesis of (2S, 5S)-2-tert-butyl-5-[(1R or lS)-3-oxocyclopentyl]-5-phenyl-l, 3-dioxolan-4-one.
The compound was synthesized following the procedure of Example 1, step-b,
using 2-cyclopentenone instead of 2-cyclohexenone.
1HNMR (CDCl3): 7.70-7.26 (m, 5ArH), 5.40 (d, 1H), 2.88 (m, 1H), 2.37-1.05 (m, 6H), 0.90 (s, 9H), IR (DCM): 1791 and 1746 cm-1
Step-b; Synthesis of (2S, 5S)-2-tert-butyl-5-[(1R or 1S. 3R or 3S)-3-hydroxycyclopentyl]-5-phenyl-l, 3-dioxolan-4-one.
The compound was synthesized following the procedure of Example 2, step-a,
using (2S, 5S)-2-tert-butyl-5-[(lR or lS)-3-oxocyclopentyl]-5-phenyl-l, 3-dioxolan-4-one
instead of (2S, 5S)-2-tert-butyl-5-[(lR or lS)-3-oxocyclohexyl]-5-phenyl-l, 3-dioxolan-4-
one.
1HNMR (CDCl3): 7.68-7.25 (m, 5ArH), 5.49 (d, 1H), 4.33-4.27 (m, 1H), 2.67-2.62 (m, 1H), 1.97-1.25 (m, 6H), 0.91 (s, 9H), IR (DCM): 1790 cm-1
Step-c; S ynthesis of (2S, 5S)-2-tert-butyl-5-[(1R or 1S. 3R or 3S)-3-fluorocyclopentyl]-5-phenyl-1 .3-dioxolan-4-one.
The compound was synthesized following the procedure of Example 2, step-b,
using (2S, 5S)-2-tert-butyl-5-[(1R or 1S, 3R or 3S)-3-hydroxycyclopentyl]-5-phenyl-l, 3-
dioxolan-4-one instead of (2S, 5S)-2-tert-butyl-5-[(lR or 1S, 3R or 3S)-3-
hydroxycyclohexyl]-5-phenyl-l, 3-dioxolan-4-one.
IR (DCM): 1791cm-1
Step-d: Synthesis of (2S)-[(lR or 1S. 3R or 3S)-3-fluorocyclopentyl]-2-hydroxy-2-phenylacetic acid.


The compound was synthesized following the procedure of Example 1, step-c, using (2S, 5S)-2-tert-butyl-5-[(1R or 1S, 3R or 3S)-3-fluorocyclopentyl]-5-phenyl-l, 3-dioxolan-4-one instead of (2S, 5S)-2-tert-butyl-5-[(lR or lS)-3-oxocyclohexyl]-5-phenyl-1, 3-dioxolan-4-one.
1HNMR (CDC13): 7.67-7.25 (m, 5ArH), 5.2?-4.99;(m, 1H), 3.29-3.18 (m, 1H), 2.03-1.25 (m, 6H), IR (DCM): 1726 cm-1
Step-e: Synthesis of (2S)-(1α, 5α. 6α)-6-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl]-2-(1R or 1S, 3Ror 3S)-3-fluorocyclopentyl]-2-hydroxy-2-phenylacetamide
The title compound was synthesized following the procedure of Example 1, step-e,
using (2S)-[(1R or 1S, 3R or 3S)-3-fluorocyclopentyl]-2-hydroxy-2-phenylacetic acid
instead of (2S)-[(1R or 1S)-3-oxocyclohexyl]-2-hydroxy-2-phenylacetic acid.
1HNMR (CDCl3): 7.67-7.19 (m, lOArH), 5.2 (m, 1H), 3.52 (s, 2H), 3.08-2.97 (m, 6H), 2.33-1.25 (m, 8H), IR(DCM): 1653 cm-1
Example 4
Preparation of (2S)-(1α, 5α, 6α)-6-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl]-2-[(lR or lS)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetamide (Compound No. 4A & 4B)
Step-a; Synthesis of (2S. 5S)-2-tert-butyl-5-[1R or 1S)-3,3-difluorocyclohexyl]-5-phenyl-1, 3-dioxolan-4-one.
To a solution of (2S, 5S)-2-tert-butyl-5-[(lR or lS)-3-oxocyclohexyl]-5-phenyl-
l,3-dioxolan-4-one (1 mmol) in chloroform cooled to 0°C, was added diethylamino sulfur
trifluoride (DAST) (4 mmol). The reaction mixture was stirred at room temperature
overnight. The reaction mixture was cooled and quenched with water. The organic layer
was separated and the aqueous layer was extracted with dichloromethane. The organic
layer was dried and the residue obtained after removal of solvents was purified by column
chromatography (100-200 mesh, silica gel), eluting the compound with 5% ethyl acetate-
hexane mixture.
1HNMR (CDCl3): 7.67-6.29 (m, 5ArH), 5.39 (d, 1H), 2.32 (m, 1H), 2.1-1.25 (m, 8H), 0.93 (s, 9H), IR (DCM): 1792 cm-1
Step-b: Synthesis of (2S)-[(1R or lS)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetic acid.
The compound was synthesized following the procedure of Example 1, step-c,
using (2S)-2-tert-butyl-5-[(lR or lS)-3,3-difluorocyclohexyl]-5-phenyl-l,3-dioxolan-4-
one instead of (2S)-2-tert-butyl-5-[(lR or lS)-3-oxocyclohexyl]-5-phenyl-l,3-dioxolan-4-
one.
m.pt: 144-147°C,IR(KBr): 1694 cm-1

Step-c: Synthesis of (2S)-(1α, 5α, 6α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyr)-2-[(1R or 1S)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetamide
The above compound was synthesized following the procedure of Example 1, step-
e, using (2S)-2-[(lR or lS)-3,3-difluorocyclohexyl]-2-phenylacetic acid instead of (2S)-2-
[(1R or 1S)-3-oxocyclohexyl]-2-hydroxy-2-phenylacetic acid.
Compound 4A: 1HNMR (CDC13): 7.57-7.13 (m, lOArH), 3.53 (s, 2H), 2.99 (m, 3H), IR (DCM): 1653 cm-1
Compound 4B; 1HNMR (CDC13): 7.59-7.19 (m, lOArH), 3.53 (s, 2H), 3.06 (m, 3H), IR (DCM): 1652 cm-1
Compounds 4A & 4B are a pair of diastereomers.
Example 5
Preparation of (2S)-(1α, 5α, 6α)-6-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl]-2[(lR or lS)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide (Compound No. 5A & 5B)
Step-a: Synthesis of (2S, 5S)-2-tert-butyl-5-[(lR or 1S)-3.3-difluorocyclopentyl]-5-phenyl-1,3-dioxolan-4-one.
The compound was synthesized following the procedure of Example 4, step-a,
using (2S, 5S)-2-tert-butyl-5-[(lR or lS)-3-oxocyclopentyl]-5-phenyl-l,3-dioxolan-4-one
instead of (2S, 5S)-2-tert-butyl-5-[(lR or lS)-3rOxocyclohexyl]-5-phenyl-l,3-dioxolan-4-
one.
1HNMR (CDCl3): 7.67-7.25 (m, 5H), 5.42 (s, 1H), 2.80-2.76 (m, 1H), 2.21-1.74 (m, 6H), 0.95 (s, 9H), IR (DCM): 1793 cm-1
Step-b: Synthesis of (2S)-[(1R or lS)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetic acid.
The compound was synthesized following the procedure of Example 1, step-c
using (2S)-2-tert-butyl-5-[(lR or lS)-3,3-difluorocyclopentyl]-5-phenyl-l,3-dioxolan-4-
one instead of (2S)-2-tert-butyl-5-[(lR or lS)-3-oxocyclohexyl]-5-phenyl-l,3-dioxolan-4-
one.
m.pt: 127°C, 1HNMR (CDCl3): 7.63-7.25 (m, 5H), 3.22-3.10 (m, 1H), 2.26-1.25 (m, 6H).
IR (DCM): 1712 cm-1
Step-c: Synthesis of (2S)-(1α, 5α, 6α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyl]-2-[(R or 1S)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide.
The title compound was synthesized following the procedure of Example 1, step-e,
using (2S)-[(1R or lS)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetic acid instead of
(2S)-[(1R or 1S)-3-oxocyclohexyl]-2-hydroxy-2-phenylacetic acid.

Compound 5A; 1HNMR (CDC13): 7.55-7.19 (m, 10ArH), 6.23 (brs, 1H), 3.52 (s, 2H), 3.38 (s, 1H), 3.30-3.22 (m, 1H), 3.06-2.98 (m,3H), 2.36-2.32 (m, 2H), 2.14-2.04 (m, 4H), 1.56-1.25 (m, 4H), IR (DCM): 1656 cm-1
Compound 5B: 1HNMR (CDCl3): 7.54-7.19 (m, lOArH), 6.30 (brs, 1H), 3.52 (s, 2H), 3.37-3.24 (m, 2H), 3.06-2.98 (m, 3H), 2.36-1.25 (m, 10H), IR (DCM): 1652 cm-1
Compounds 5A and 5B are a pair of diastereomers.
Example 6
Preparation of (2R)-(1α, 5α, 6α)-6-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl]-2-[(lR or lS)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide (Compound No. 6)
Step-a: Synthesis of (2R, 5R)-2-tert-butyl-5-phenyl-l,3-dioxolan-4-one.
This compound was synthesized following the procedure described in J. Org.
Chem. 2000; 65: 6283-6287.
Step-b; Synthesis of (2R, 5R)-2-tert-butyl-5-[(lR or 1S)-3-oxocyclopentyl]-5-phenyl-1,3-dioxolan-4-one.
The compound was synthesized following' the procedure of Example 1, step-b,
using (2R, 5R)-2-tert-butyl-5-phenyl-l,3-dioxolan-4-one instead of (2S, 5S)-2-tert-butyl-
5-phenyl-l,3-dioxolan-4-one and 2-cyclopentenone instead of 2-cyclohexenone.
Step-c; Synthesis of (2R, 5R)-2-tert-butyl-5-[(1R or lS)-3.3-difluorocyclopentyl]-5-phenyl-1,3 -dioxolan-4-one.
The compound was synthesized following the procedure of Example 4, step-a,
using (2R, 5R)-2-tert-butyl-5-[(lR or lS)-3-oxocyclopentyl]-5-phenyl-l,3-dioxolan-4-one
instead of (2S, 5S)-2-tert-butyl-5-[(1R or 1S)-3-oxocyclopentyl]-5-phenyl-l,3-dioxolan-4-
one.
1HNMR (CDCl3): 7.67-7.25 (m, 5ArH), 5.43 (s, 1H), 2.79-2.76 (m, 1H), 2.23-1.67 (m, 6H), 0.92 (s, 9H), IR (DCM): 1792 cm-1
Step-d: Synthesis of (2R)-[(1R or lS)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetic acid.
The compound was synthesized following the procedure of Example-1, Step-c,
using (2R, 5R)-2-tert-butyl-5-[(lR or lS)-3,3-difluorocyclopentyl]-5-phenyl-l,3-dioxolan-
4-one instead of (2S, 5S)-2-tert-butyl-5-[(lR or lS)-3-oxocyclohexyl]-5-phenyl-l,3-
dioxolan-4-one.
1HNMR (CDCl3): 7.64-7.25 (m, 5ArH), 3.22-3.10 (m, 1H), 2.26-1.43 (m, 6H), IR (KBr):
1724 cm-1
Step-e: Synthesis of (2R)-(1α. 5α. 6α)-6N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl]-2-[1R or
1S)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide.

The title compound was synthesized following the procedure of Example 1, step-e, using (2R)-[(1R or lS)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetic acid instead of (2S)-[(1R or lS)-3-oxocyclohexyl]-2-hydroxy-2-phenylacetic acid.
1HNMR (CDCl3): 7.54-7.19 (m, lOArH), 5.77 (brs, 1H), 3.52 (s, 2H), 3.30-2.98 (m, 6H), 2.35-2.31 (m, 2H), 2.13-1.10 (m, 7H), IR (DCM): 1651cm-1
Example 7
Preparation of (2S)- (1α, 5α, 6α)-6-N- [3-(2-(3,4-methylenedioxy phenyl) ethyl)-3-azabicyclo [3.1.0]-hexyl]-2-[(lR or lS)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetamide (Compound No. 7)
Step-a; Synthesis of 3,4-methylenedioxyphenethyl bromide.
The compound was synthesized following the procedure described in EP
0388054A1.
Step-b: Synthesis of (1α, 5α, 6α)-6-tert-butoxvcarbonylamino-3-azabicyclo[3.1.0]hexane
The compound was synthesized following the procedure described in T.F. Braish et.al., Synlett, 1100,(1996).
Step-c: Synthesis of (1α, 5α, 6α)-3N-[2-(3,4-methylenedioxvphenyl)ethyl]-6-[t-butoxycarbonyl amino]-3-azabicyclo-[3.1 .0]hexane
A solution of compound obtained, in . step b (1.5 mmol) and
methylenedioxyphenethyl bromide (1 mmol) in acetonitrile (10 ml) containing potassium
carbonate (3 mmol) and potassium iodide (1.5 mmol) was refluxed for 6 hours. The
solvent was removed under reduced pressure, the residue was taken in ethyl acetate, and
washed with water. The organic layer was then dried and the residue obtained after
removal of solvent was purified by column chromatography (100-200 mesh, silica gel),
using ethyl acetate-hexane mixture as eluent.
1HNMR (CDCl3): 6.72-6.59 (m, 3ArH), 5.9 (s, 2H), 3.12 (d, 2H), 2.75 (s, 1H), 2.54 (m, 4H), 2.36 (d,2H), 1.43 (d, 1H).
Step-d: Synthesis of (1α, 5α, 6α)-3-N-[2-(3.4-methylenedioxyphenyl)ethyl]-3-azabicyclo[3.1.0]hexane hydrochloride.
The compound of step-c was dissolved in ethyl acetate and ethyl acetate saturated
with hydrochloric acid was added to the above reaction'mixture and stirred overnight at
room temperature. The solvent was removed under reduced pressure and the residue was
washed with hexane and dried.
m. pt: 232 °C

Step-e; Synthesis of (2S)-(1α,5α,6α)-6-N-[3-(2-(3,4-methylenedioxvphenyl)ethyl) -3-
azabicyclo[3.1.0]-hexyl-2-[(1R or lS)-3,3-difluorocyclohexyl]-2-hydroxy-2-
phenylacetamide
A solution of (2S)-[(1R or lS)-3, 3-difluorocyclohexyl]-2-hydroxy-2-phenylacetic
acid (1 mmol) and the amine of step-d (1 mmol) in dimethylformamide (5 ml) was cooled
to 0°C. Hydroxybenzotriazole (HOBT) (1 mmol) and N-methylmorpholine (4 mmol) were
added to the reaction mixture and the reaction mixture was stirred at 0°C for 30 minutes.
1-(3-dimethyl amino propyl)-3-ethyl-carbodiimide hydrochloride was added to the
reaction mixture and stirred at 0°C for 1 hour and then at room temperature for 1 day. The
reaction mixture was poured into saturated bicarbonate solution and extracted with ethyl
acetate. The organic layer was washed with water, dried and the residue obtained after
removal of solvent was purified by column chromatography (100-200 mesh, silica gel),
eluting the compound with 50% ethyl acetate-hexane mixture.
1HNMR (CDC13): 7.53-7.3 (m, 5ArH), 6.7-6.58 (m, 3ArH), 5.9 (s, 2H), 3.15 (t, 2H).
IR(KBr): 1662 cm-1
Example 8
Preparation of (2S)-(1α, 5α, 6α)-6-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-
azabicyclo[3.1.0]-hexyl]-2-[(lR or lS)-3,3-difluorocvciopenryl]-2-hydroxy-2-
phenylacetamide (Compound No. 8A & 8B)
The title compound was synthesized following the procedure of Example 7, step-e,
using (2S)-[(1R or lS)-3, 3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetic acid instead
of (2S)-[(1R or 1S)-3, 3-difluorocyclohexyl]-2-hydroxy-2-phenyl acetic acid.
Compound 8A: 1HNMR (CDCl3): 7.57-7.26; (m,: 5ArH), 6.71-6.58 (m, 3H), 6.30 (brs, 1H), 5.90 (s, 2H), 3.27-2.02 (m, 10H), 1.76-1.23 (m, 8H).
Compound 8B: 1HNMR (CDCl3): 7.54-7.26 (m, 5ArH), 6.70-6.57 (m, 3ArH), 6.32 (brs, 1H), 5.89 (s, 2H), 3.27-2.31 (m, 9H), 1.85-1.25 (m, 10H)
IR(DCM): 1653 cm-1
Compounds 8 A and 8B are a pair of diastereomers.
Example 9
Preparation of (2R)-(1α, 5α, 6α)-6-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(lR or lS)-3,3-difluorocydopentyl]-2-hydroxy-2-phenylacetamide. (Compound No. 9)
The title compound was synthesized following the procedure of Example 7, Step-e,
using (2R)-[(1R or lS)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetic acid instead of
(2S)-[(1R or lS)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetic acid.

1HNMR (CDCl3): 7.55-7.26 (m, 5ArH), 6.70-6.57 (m, 3H), 6.30 (brs, 1H), 5.9 (s, 2H), 3.42-2.84 (m, 5H), 2.58-1.39 (m, 13H), IR (DGM):; 1651cm-1
Example 10
Preparation of (2S)-(1α, 5α, 6α)-6-N-[3-(2-(3,4-methylenedioxvphenyl)ethyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S, 3R or 3S)-3-fluorocyclohexyl]-2-hydroxy-2-phenylacetamide. (Compound No. 10)
The title compound was synthesized following the procedure of Example 7, Step-e,
using (2S)-[(1R or 1S, 3R or 3S)-3-fluorocyclohexyl]-2-hydroxy-2-phenylacetamide
instead of (2S)-[(1R or lS)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetic acid.
1HNMR (CDCl3): 7.54-7.28 (m, 5ArH), 6.7-6.57 (m, 3ArH), 5.89 (s, 2H), 4.5 (m, 1H), 3.13 (t, 2H), IR (KBr): 1661 cm-1
Example 11
Preparation of (2S)-(1α, 5α, 6α)-6-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S, 3R or 3S)-3-fluorocyclopentyl]-2-hydroxy-2-phenylacetamide. (Compound No. 11)
The title compound was synthesized following the prpcedure of Example 7, Step-e,
using (2S)-[(1R or 1S, 3R or 3S)-3-fluorocyclopentyl]-2-hydroxy-2-phenylacetamide
instead of (2S)-[(1R or lS)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetic acid.
1HNMR (CDCl3): 7.54-7.25 (m, 5ArH), 6.70-6.57 (m, 3ArH), 5.92 (s, 2H), 5.29-5.01 (m, 1H), 3.16-2.31 (m, 9H), 2.04-1.25 (m, 10H), IR(KBr): 1650 cm-1
Example 12
Preparation of (2S)-(1α, 5α, 6α)-6-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hexyl]-2- [(1R or 1S)-3,3-difluorocyclohexyl] -2-hydroxy-2-phenylacetamide (Compound No. 12A & 12B)
Step-a; Synthesis of (lα, 5α, 6α)-3-N-(4-methvr-3-pentenyl)-6-[t-butoxycarbonyl amino]-3-azabicyclo[3.1,0]hexane.
The compound was synthesized following he procedure of Example 7, Step-c,
using 5-bromo-2-methyl pent-3-ene instead of 3,4-dimethylenedioxyphenethyl bromide.
1HNMR (CDCl3): 5.07 (t, 1H), 4.56 (bs, 1H), 3.10 (d, 1H), 2.76 (s, 1H), 2.36-2.03 (m, 6H), 1.67-1.25 (m, 18H), IR (KBr): 1706 cm-1
Step-b: Synthesis of (1α, 5α, 6α)-3-N-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexane hydrochloride
The compound was synthesized following the procedure of Example 7, step-d,
using (1α, 5α, 6α)-3-N- (4-methyl-3-pentenyl)-6-[t-butoxycarbonyl amino]-3-azabicyclo
[3.1.0] hexane instead of (1α, 5α, 6α)-3-N- [2-(3,4-methylenedioxyphenyl) ethyl]-6-[t-
butoxycarbonyl amino]-3-azabicyclo [3.1.0] hexane.
m.pt.: 230°C

Step-c: Synthesis of (2S)-(1α, 5α, 6α)-6-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetamide
A solution of (2S)-[(1R or lS)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenyl acetic
acid (1 mmol) and compound of step-b, in DMF (5 ml) was cooled to 0 °C. Hydroxy
benzotriazole HOBT (1 mmol) and N-methylmorpholine NMM (4 mmol) were added to
reaction mixture and stirred for 30 minutes at 0 °C. l-(3-dimethylaminopropyl)-3-ethyl
carbodiimide hydrochloride (EDC. HC1) was then added to the reaction mixture and
stirred for 1 hour at 0 °C followed by stirring at room temperature overnight. The reaction
mixture was poured into saturated bicarbonate solution and extracted with ethyl acetate.
The organic layer was washed with water, dried and the residue obtained after removal of
solvents was purified by column chromatography (100-200 mesh, silica gel), eluting the
compound with 30% ethyl acetate-hexane mixture.
Compound No. 12A: 1HNMR (CDC13): 7.59-7.29 (m, 5ArH), 5.04 (t, 1H), 3.13 (t, 2H), IR(DCM): 1653 cm-1
Compound No. 12B: 1HNMR (CDCl3): 8.0-7.29 (m, 5ArH), 5.04 (t, 1H), 3.1 (t, 2H), IR (DCM): 1667 cm-1
Compounds 12A and 12B are a pair of diastereomers.
Example 13
Preparation of (2S)-(1α, 5α, 6α)-6-N-[3-(4-methyl-3-pentehyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S)-3,3-difluorocyclopentyl],-2-hydroxy-2-phenylacetamide (Compound No. 13A & 13B)
The compound was synthesized following the procedure of Example 12, step-c, using (2S)-[(1R or lS)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetic acid instead of (2S)-[(1R or lS)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetic acid.
Compound 13A; 1HNMR (CDCl3): 7.60-7.26 (m, 5ArH), 6.30 (brs, 1H), 5.04 (t, 1H), 3.48-2.86 (m, 4H), 2.36-1.40 (m, 21H)
Compound 13B; 1HNMR (CDCl3): 7.54-7.26 (m, 5ArH), 6.44 (brs, 1H), 5.03 (t, 1H), 3.30-2.85 (m, 4H), 2.41-0.93 (m, 21H)
IR(DCM): 1655 cm-1
Compounds 13 A and 13B are a pair of diastereomers.
Example 14
Preparation of (2R)-(1α, 5α, 6α)-6-N-[3-(4-methyl-3-pentenvn-3-azabicyclo[3.1.0]-hexyl]-2-[(lR or lS)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide (Compound No. 14)

The compound was synthesized following the procedure of Example 12, step-c, using (2R)-[(1R or lS)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetic acid instead of (2S)-[(1R or lS)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenyl acetic acid.
1HNMR (CDCl3): 7.58-7.26 (m, 5ArH), 6.30 (brs, 1H), 5.04 (t, 1H), 3.26.2.86 (m, 4H), 2.35-1.25 (m, 20H), IR (DCM): 1652 cm-1
Example 15
Preparation of (2S)-(1α, 5α, 6α)-6-N-[3-(4-methyl-3-pentenyl]-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S, 3R or 3S)-3-fluorocyclohexyl]-2-hydroxy-2-phenylacetamide (Compound No. 15)
The compound was synthesized following the procedure of Example 12, step-c,
using (2S)-[(1R or 1S, 3R or 3S)-3-fluorbcyclohexyl]-2-hydroxy-2-phenylacetic acid
instead of (2S)-[(1R or lS)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetic acid.
1HNMR (CDCl3): 7.6-7.26 (m, 5ArH), 5.01 (m, 2H), 3.11 (s, 2H), IR (DCM): 1654 era-1
Example 16
Preparation of (2S)-(1α, 5α, 6α)-6-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S, 3R or 3S)-3-fluorocyclopentyl]-2-hydroxy-2-phenylacetamide (Compound No. 16)
The compound was synthesized following the procedure of Example 12, step-c,
using (2S)-[(1R or 1S, 3R or 3S)-3-fluorocyclopentyl]-2-hydroxy-2-phenylacetic acid
instead of (2S)-[(1R or lS)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetic acid.
1HNMR (CDCl3): 7.65-7.26 (m, 5ArH), 5.20 (m, 1H), 5.04 (t, 1H), 3.13-2.85 (m, 5H), 2.35-1.25 (m, 19H), IR (DCM): 1653 cm-1
Biological Activity
Radioligand Binding Assays:
The affinity of test compounds for M2 ahd M3 muscarinic receptor subtypes was determined by [3H]-N-methylscopolamine binding studies using rat heart and submandibular gland respectively as described by Moriya et al., (Life Sci, 1999,64(25): 2351-2358) with minor modifications.
Membrane preparation: Submandibular glands and heart were isolated and placed in ice cold homogenising buffer (HEPES 20 mM, 10 mM EDTA, pH 7.4) immediately after sacrifice. The tissues were homogenised in 10 volumes of homogenising buffer and the homogenate was filtered through two layers of wet gauze and filtrate was centrifuged at 500 g for 10 min. The supernatant was subsequently centrifuged at 40,000 g for 20 min.

The pellet thus obtained was resuspended in same volume of assay buffer (HEPES 20
mM, EDTA 5 mM, pH 7.4) and were stored at -70°C until the time of assay.
Ligand binding assay: The compounds were dissolved and diluted in DMSO. The
membrane homogenates (150-250 ug protein) were incubated in 250 µl of assay buffer
(HEPES 20 mM, pH 7.4) at 24-25°C for 3h. Non-specific binding was determined in the presence of 1 µM atropine. The incubation was terminated by vaccum filtration over GF/B fiber filters (Wallac). The filters were then washed with ice cold 50 mM Tris HC1 buffer (pH 7.4). The filter mats were dried and bound radioactivity retained on filters was counted. The IC50 & Kd were estimated by using the non-linear curve-fitting program
using G Pad Prism software. The value of inhibition constant Ki was calculated from competitive binding studies by using Cheng & Prusoff equation (Biochem Pharmacol
1973,22: 3099-3108), Ki = IC50 /(1+L/Kd), where L is the concentration of [3H]NMS
used in the particular experiment.
Functional Experiments using isolated rat bladder:
Methodology:
Animals were euthanized by overdose of urethane and whole bladder was isolated and removed rapidly and placed in ice cold Tyrode buffer with the following composition (mMol/L) NaCl 137; KC1 2.7; CaCl2 1.8; MgCl2 0.1; NaHC03 11.9; NaH2P04 0.4; Glucose 5.55 and continuously gassed with 95% 02 and 5 % C02.
The bladder was cut into longitudinal strips (3 mm wide and 5-6 mm long) and mounted in 10 ml organ baths at 30° C, with one end connected to the base of the tissue holder and the other end connected to a polygraph through a force displacement transducer. Each tissue was maintained at a constant basal tension of 2 g and allowed to equilibrate for 1 hour during which the PSS was changed every 15 min. At the end of equilibration period, the stabilization of the tissue contractile response was assessed with 1 µMol/L of Carbachol consecutively for 2-3 times. Subsequently, a cumulative concentration response curve to carbachol (10-9 mol/L to 3 X 10-5 mol/L) was obtained. After several washes, once the baseline was achieved, cumulative concentration response curve was obtained in the presence of NCE (NCE added 20 min. prior to the second CRC).
The contractile results were expressed as % of control E max. ED50 values were calculated by fitting a non-linear regression curve (Graph Pad Prism). pKB values were calculated by the formula pKB = -log[(molar concentration of antagonist/(dose ratio-1))] where,

dose ratio = ED50 in presence of antagonist/ED50 in the absence of antagonist. The results of the in-vitro tests are listed in Table I. In vitro tests
Table-I
(Table Removed)
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

We claim:
1. A 3,6 disubstituted azabicyclo hexane derivative having the structure of Formula I:
(Formula Removed)
Formula I
wherein
Ar represents an aryl; R1 represents hydroxy;
R2 represents C3-C7 cycloalkyl ring in which any 1-4 hydrogen atoms are substituted with halogen (e.g. F, CI, Br, I), carbamoyl or lower alkyl; W represents (CH2)P, where p represents 0 to 1; X represents no atom; Y represents no atom; R3 represents hydrogen or lower alkyl; R6 and R7 are independently selected from H, lower alkyl,; and R4 represents C1-C15 saturated or unsaturated aliphatic hydrocarbon (straight chain or branched) in which any 1 to 6 hydrogen atoms may be substituted with the group independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl having 1 to 2 hetero atoms selected from the group consisting of nitrogen, oxygen and sulphur atoms.
2. A compound as claimed in claim 1 selected from the group consisting of:
(2S)-(1α, 5α, 6α)-6-N-[3-benzyl-3- azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S)-3-oxocyclohexyl]-2-hydroxy-2-phenylacetamide
(2S)-(1α, 5α, 6α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyl]-2[(1R or 1S, 3Ror 3 S)-3 -fluorocyclohexyl ] -2-hydroxy-2-phenylacetamide
(2S)-(1α, 5α, 6α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S, 3Ror 3 S)-3 -fluorocyclopentyl] -2-hydroxy-2-phenylacetamide
(2S)-(1α, 5α, 6α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S)-3, 3-difluorocyclohexyl]-2-hydroxy-2-phenylacetamide
(2S)-(1α, 5α, 6α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide
(2R)-(1α, 5α, 6α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide
(2S)- (1α, 5α, 6α)-6-N- [3-(2-(3,4-methylenedioxyphenyl) ethyl)-3-azabicyclo [3.1.0]-hexyl]-2-[(lR or lS)-3, 3-difluorocyclohexyl]-2-hydroxy-2-phenylacetamide
(2S)-(1α, 5α, 6α)-6-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(lR or lS)-3, 3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide
(2R)-(1α, 5α, 6α)-6-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(lR or lS)-3, 3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide.
(2S)-(1α, 5α, 6α)-6-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S, 3R or 3S)-3-fluorocyclohexyl]-2-hydroxy-2-phenylacetamide.
(2S)-(1α, 5α, 6α)-6-N-[3-(2-(3, 4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S, 3R or 3S)-3-fluorocyclopentyl]-2-hydroxy-2-phenylacetamide.
(2S)-(1α, 5α, 6α)-6-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(lR or lS)-3, 3-difluorocyclohexyl]-2-hydroxy-2-phenylacetamide
(2S)-(1α, 5α, 6α)-6-N-[3-(4-methyl-3-pentenyl)-3-azabicycloi3.1.0]-hexyl]-2-[(lR or lS)-3, 3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide
(2R)-( 1α, 5α, 6α)-6-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S)-3, 3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide
(2S)-(1α, 5α, 6α)-6-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R
or 1S, 3R or 3S)-3-fluorocyclohexyl]-2-hydroxy-2-phenylacetamide
(2S)-(1α, 5α, 6α)-6-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R
or 1S, 3R or 3S)-3-fluorocyclopentyl]-2-hydroxy-2-phenylacetamide
3. A pharmaceutical composition of a compound as claimed in claim 1 and 2, comprising a therapeutically effective amount of compound together with pharmaceutically acceptable carriers, excipients or diluents.
4. The use of the compounds according to claim 1, in the preparation of medicaments for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and .gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic; receptor.
5. The use according to claim 4 wherein the disease or disorder is urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel-syndrome, obesity, diabetes, and gastrointestinal hyperkinesis
6. A process for preparing 3,6-disubstituted azabicyclo hexane derivative, as claimed in claim 1 having the structure of Formula I,
(Formula Removed)
comprising
(a) condensing a compound of Formula VI with a compound of Formula V (P is a protecting group for an amino group and is selected from the group consisting of benzyl and t-butyloxy carbonyl groups) in the presence of a condensing agent selected from the group consisting of 1-(3-dimethyl amino propyl)-3 -ethyl carbodiimide hydrochloride (EDC) and 1,8-diazabicyclo [5.4.0] undec-7-ene 1,8-diazabicyclo [5.4.0] undec-7-ene in a suitable solvent selected from the group consisting of N,N-dimethylformamide, dimethylsulfoxide, toluene and xylene is carried out at a temperature ranging from about 0°C to about140°C.
(Formula Removed)
Formula VI Formula V
to give a protected compound of Formula VII
(Formula Removed)
Formula VII
(b) deprotecting the compound of Formula VII to give an unprotected
compound of Formula VIII in the presence of a deprotecting agent
selected from the group consisting of palladium on carbon,
trifluoroacetic acid (TFA) and hydrochloric acid in a suitable
organic solvent selected from the group consisting of methanol,
ethanol, tetrahydrofuran and acetonitrile.
(Formula Removed)
Formula VIII
(c) N-alkylating or benzylating the compound of Formula VIII with a
suitable alkylating or benzylating agent, L-R4 wherein L is any
leaving group selected from the group consisting of halogen, O-
mestyl and O-tosyl groups, in a suitable organic solvent selected
from the group consisting of N,N-dimethylformamide,
dimethylsulfoxide, tetrahydrofuran and acetonitrile, to give
compounds of Formula I.